TY - JOUR
T1 - Heart Failure With Preserved Ejection Fraction in Patients With Obesity
T2 - A Growing Cardiometabolic Concern
AU - Sindone, Andrew P.
AU - Abhayaratna, Walter P.
AU - Chan, Alicia
AU - Leung, Melissa
AU - Hopper, Ingrid
AU - Amerena, John
AU - De Pasquale, Carmine G.
AU - Burdeniuk, Christine
AU - Coats, Andrew J.S.
AU - Atherton, John J.
PY - 2025/10
Y1 - 2025/10
N2 - Heart failure (HF) affects approximately 2.1% of adult Australians and is associated with substantial morbidity and mortality. Approximately half of all patients with HF have HF with a preserved ejection fraction (HFpEF), which is increasing in incidence driven by an ageing population and an increasing prevalence of obesity and diabetes. Obesity drives HFpEF via multiple mechanisms, with a linear relationship between various anthropometric measures and the risk of developing HFpEF. Heightened diagnostic awareness is required to identify patients with obesity-associated HFpEF, given the availability of therapeutics that have been shown to improve quality of life and clinical outcomes, including sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and glucagon-like peptide-1 agonist-based therapies. This review provides an overview of our current understanding of the impact of obesity on the development of HFpEF and outlines an approach to diagnosis and new therapeutic options.
AB - Heart failure (HF) affects approximately 2.1% of adult Australians and is associated with substantial morbidity and mortality. Approximately half of all patients with HF have HF with a preserved ejection fraction (HFpEF), which is increasing in incidence driven by an ageing population and an increasing prevalence of obesity and diabetes. Obesity drives HFpEF via multiple mechanisms, with a linear relationship between various anthropometric measures and the risk of developing HFpEF. Heightened diagnostic awareness is required to identify patients with obesity-associated HFpEF, given the availability of therapeutics that have been shown to improve quality of life and clinical outcomes, including sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and glucagon-like peptide-1 agonist-based therapies. This review provides an overview of our current understanding of the impact of obesity on the development of HFpEF and outlines an approach to diagnosis and new therapeutic options.
KW - Cardiovascular disease
KW - Heart failure
KW - Obesity
UR - http://www.scopus.com/inward/record.url?scp=105015965792&partnerID=8YFLogxK
U2 - 10.1016/j.hlc.2025.08.010
DO - 10.1016/j.hlc.2025.08.010
M3 - Review article
AN - SCOPUS:105015965792
SN - 1443-9506
VL - 34
SP - 1033
EP - 1040
JO - Heart Lung and Circulation
JF - Heart Lung and Circulation
IS - 10
ER -
